An Open-label, Phase 1/2 Study Of Inotuzumab Ozogamicin In Subjects With Relapsed Or Refractory Cd22-positive Acute Lymphocytic Leukemia

Trial Profile

An Open-label, Phase 1/2 Study Of Inotuzumab Ozogamicin In Subjects With Relapsed Or Refractory Cd22-positive Acute Lymphocytic Leukemia

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Inotuzumab ozogamicin (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 02 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 08 Dec 2015 Results of correlative analysis presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 01 May 2015 Planned primary completion date changed from 1 Jul 2014 to 1 Aug 2014 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top